Browsing Tag
CSL Seqirus
3 posts
CSL Seqirus reports stronger immune response with enhanced flu vaccine in adults over 50
CSL Seqirus has published pivotal Phase III results from 7,699 adults showing superior immune responses versus an adjuvanted egg-based flu vaccine, while the study design leaves real-world comparative effectiveness as a separate question.
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
CSL Seqirus data show cell-based flu vaccine provides 20% stronger protection against lab-confirmed influenza
Find out how CSL Seqirus’s real-world data reveal a 20% protection boost for its cell-based flu vaccine over traditional egg-based shots.